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Introduction: The release of tumor necrosis factor (TNF-a) is increased in sarcoidosis
patients. TNF-a exerts its effect by binding to specific cell surface receptors. There are
only fragmentary data concerning the expression of tumor necrosis factor receptors
(TNFRs) on bronchoalveolar lavage fluid (BALF) and peripheral blood (PB) lymphocytes.
The aim of the study was to evaluate TNFRI (CD120a) and TNFRII (CD120b) expression on T
cells and the level of soluble TNFRs in specimens of patients with different clinical
manifestation and clinical outcome of sarcoidosis.
Material and methods: We examined 49 patients with newly diagnosed pulmonary
sarcoidosis. TNFRI and TNFRII density on CD4+ and CD8+ BALF and PB cells surface was
estimated using monoclonal antibodies and a flow cytometry technique. The level of TNFRs
in PB serum and BALF cell culture supernatant (CCS) was measured using ELISA.
Immunological analyses were also performed on PB samples collected from 10 healthy
volunteers.
Results: The level of soluble TNFRI (sTNFRI) in PB serum was similar in sarcoidosis patients
and healthy subjects, whereas the concentration of sTNFRII in serum was significantly
higher in the sarcoidosis group (Po0.001). Patients without acute symptoms of sarcoidosis,
patients with radiological stage II/III as well as patients with further disease progression
showed a tendency to higher levels of sTNFRs in PB serum and lower levels of sTNFRs in
BALF CCS compared to Lo¨fgren syndrome and radiological stage I subjects, and patients
with spontaneous resolution of sarcoidosis.
More than 80% of BALF and PB lymphocytes of sarcoidosis patients expressed both CD120a
and CD120b antigens. The percentage of double-positive CD4+CD120a+ and CD4+CD120b+Elsevier Ltd. All rights reserved.
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R. Kieszko et al.646cells in PB was significantly higher (Po0.005) in sarcoidosis patients than in healthy
subjects. The highest percentage of CD4+CD120a+ and CD4+CD120b+ lymphocytes in BALF
was determined in patients with acute disease, and in PB of patients with further
spontaneous improvement.
Conclusion: The evaluation of sTNFRs and TNFRs expression on T-helper cells may be
useful in the estimation of sarcoidosis activity.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Sarcoidosis is a systemic granulomatous disease of unknown
origin that predominantly affects the lung. The disease is
characterized by lymphocytic alveolitis and the formation of
a noncaseating, epithelioid granuloma with the predomi-
nance of CD4+ Th cells and macrophages. The cells release
chemokines and cytokines, which results in cellular prolif-
eration and granuloma formation.1
Tumor necrosis factor (TNF-a) plays a key role in the
pathogenesis of various infections and inflammatory dis-
eases. The major source of TNF-a are activated monocytes
(macrophages), though the cytokine is also released by T
cells. Biological effects of TNF-a include local activation of
vascular endothelium, an increase in vascular permeability,
an increase in the expression of adhesion molecules on blood
vessel endothelium, and an increase in class II MHC
molecules expression.2,3
On the basis of its macrophage-stimulating capacity
and inflammatory cell accumulation, TNF-a can be
classified as a Th1-type, pro-inflammatory cytokine.
The release of TNF-a is increased in the lung of patients
with pulmonary sarcoidosis.4,5 TNF-a initiates the
development of giant and epithelial cells. It is responsible
for granuloma formation in the lung. Chronic overexpression
of TNF-a and INF-g may lead to the progression of
inflammation in chronic sarcoidosis patients.6 The estima-
tion of TNF-a released by alveolar macrophages may help to
find a group of patients with an increased risk of disease
prolongation and the development of unfavorable sarcoido-
sis course.7
TNF-a exerts its effect by binding to specific cell surface
receptors. Two types of TNF receptors, 55-kD receptor
(TNFRI, CD120a) and 75-kD receptor (TNFRII, CD120b), have
been identified. Both types show high binding affinity of
TNF-a. TNFRI is the main signaling receptor and is ubiquitous
in human tissues, whereas TNFRII expression appears to be
restricted to myeloid cells. These receptors are enzymati-
cally cleaved from cell surface and form soluble TNF
receptors: sTNFRI and sTNFRII. sTNFRs may inhibit TNF-a
bioactivity, acting as TNF-a antagonists, or may stabilize the
trimeric structure of TNF-a, and therefore may prolong its
bioactivity. TNF-a release would lead to a subsequent
induction of TNFRs production as a part of normal regulatory
feedback mechanism.8–10 Increased levels of TNFRs have
been reported in serum and bronchoalveolar lavage fluid
(BALF) of sarcoidosis subjects.11–14 Recent studies have
suggested that serum sTNFRII level assessment may serve as
a prognostic factor of a chronic sarcoidosis course. The
analysis of sTNFRII concentration in BALF and serum may be
also useful in treatment planning.13The studies on TNFRs as an activation marker concentrate
on a soluble form of the receptors. So far the investigations
have been focused on the level of sTNFRs in peripheral blood
(PB) serum and BALF cells culture supernatant (CCS) of
sarcoidosis patients. But the expression of the receptors on
T cells from different specimens of patients with sarcoidosis
was only fragmentary analyzed.
The aim of our study was to assess the level of sTNFRs in
PB serum and BAL CCS, and to determine the receptor
expression on BALF and PB cells in sarcoidosis patients with
different clinical presentation, radiological stage, and
clinical outcome of the disease.Material and methods
Study population
The study population comprised 49 Polish Caucasian patients
(the mean age of 39.3711.7 years; 25 female and 24 male
subjects, all nonsmokers) with newly diagnosed sarcoidosis.
The diagnosis of sarcoidosis was established using defined
criteria including histopathological confirmation. None of
the patients received steroid therapy or other immunosup-
pressive agents before bronchoscopy. Lo¨fgren syndrome
(fever, bilateral hilar adenopathy, erythema nodosum, and
arthralgia; in accordance with ATS/ERS/WASOG guidelines)
was manifested in 17 patients (the mean age of 35.479.14
years).
Twenty-seven patients (the mean age of 35.6711.7 years)
showed bilateral hilar lymphadenopathy in chest X-ray
examination (radiological stage I). In 22 patients (the mean
age of 41.4711.8 years), interstitial infiltration with or
without hilar lymphadenopathy (stage II or III) were
demonstrated. We made a distinction between the radio-
graphic stage I with self-limiting clinical course, and the
stage II or III with high probability of disease progression.
The assessment of the disease included clinical features,
chest X-ray and computed tomography, lung function tests,
abdomen ultrasonography, bronchoalveolar lavage (BAL),
and routine blood tests. The follow-up examinations
(clinical tests, lung function tests, chest X-ray, and
computed tomography) were performed every 3 months.
On the basis of 1- to 2-year follow-up (the mean period of
20.2373.67 months), the patients were divided into three
groups: the group with spontaneous remission (the remission
group consisted of 22 patients), the group with long-lasting
disease without a need of treatment (the stable disease
group—12 patients), and the group with disease progression
and a need of steroid treatment (the progression group—15
patients). The decision on steroid therapy initiation and
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Table 1 Clinical characteristic of examined patients.
Characteristics Patients
Subjects N ¼ 49
Subjects with Lo¨fgren
syndrome
N ¼ 17 (34.7%)
Female/male N ¼ 25/24
Age (years) 39.3711.7
Chest X-ray stages I and II/III N ¼ 27/22 (55.1/44.9%)
Clinical outcome
Remission N ¼ 22 (44.9%)
Stable disease (n, %) N ¼ 12 (24.5%)
Progression (n, %) N ¼ 15 (30.6%)
Lung function parameters
VC % pred 91.92712.45
FEV1% pred 85.83714.44
FEV1/VC % 77.3979.69
TLC % pred 89.36712.64
DLCO % pred 93.88714.79
TNF receptors and sarcoidosis 647inclusion to the progression group was based on the
presence of severe systemic symptoms, lung function
deterioration, and disease progression, as revealed on chest
X-ray or CT scans. The remission was defined as spontaneous
recede of clinical symptoms, improvement of lung function
test results, and remission of chest X-ray changes.
The research project was approved by the Bioethic
Committee of the Medical University of Lublin in accordance
with the Guidelines for Good Clinical Practice.
Control group
The control group consisted of 10 nonsmoking, age- and sex-
matched volunteers. None of them had a clinical and
radiological evidence of lung disease or concomitant
therapy. In morphology blood examinations, there was no
evidence of inflammatory process. For the estimation of the
percentage of Tcells with TNFRs expression and serum levels
of sTNFRI and sTNFRII, only blood samples were taken.
BAL procedure, and BALF cells preparation and
culture
BAL was performed using Pentax EPM 3300 equipment. A
bronchoscope was passed transorally under the adequate
topical anesthesia with 4% lidocaine. The standard protocol
of fiberoptic performance was applied to all patients.
BALF was obtained by standard washing of the middle
lobe with seven 20-ml aliquots of pre-warmed sterile 0.9%
saline. BALF specimens, except for the first bronchial
fraction, were carefully mixed, strained through a double
layer of nylon gauze, and centrifuged to obtain cell pellet.
Cells were washed twice with phosphate-buffered saline
(PBS). Cell pellet was resuspended in RPMI 1640 medium.
Cells were counted in the Neubauer chamber, and used for
flow cytometry analysis and culture.
106 cells per ml were cultured in RPMI 1640 medium
supplemented with 2mM L-glutamine and antibiotics in 6-
well plates (Nunc, Denmark) for 24 h at 37 1C under 5% CO2.
CCS was centrifuged at 400g and stored at 80 1C for
cytokine level measurement.
PB mononuclear cells preparation and cytometric
analysis
Blood samples were taken before bronchoscopy. Lympho-
prep (Nycomed, Norway) gradient centrifugation was used
to separate PB mononuclear cells. Cells were collected and
washed twice in PBS. Serum samples were also collected and
cryopreserved at 80 1C for further ELISA performance.
Three-color flow cytometric technique was used in the
analysis of PB and BALF lymphocyte subtypes. 106 cells/ml
were incubated with different sets of fluorochrome-labeled
monoclonal antibodies. Simultest (Becton Dickinson, USA),
PE-conjugated monoclonal antibody (mAb) specific for the
type I TNF receptor (CD120a) and the type II TNF receptor
(CD120b; Caltag Laboratories, USA), FITC-conjugated mAb
anti-CD4 antigen, and PerCP-conjugated mAb anti-CD8
antigen (Becton Dickinson, USA) were used. Cells were
incubated for 20min at room temperature and immediately
analyzed in the flow cytometer FACS Calibure (BectonDickinson, USA). The mean fluorescence intensity (MFI) of
antigens was evaluated using the CellQuest software
(Becton Dickinson, USA).
Assessment of sTNFRI and sTNFRII in PB serum and
BALF CCS
The determination of soluble TNFRI and TNFRII levels was
performed using enzyme-linked immunosorbent assay (ELI-
SA) with the commercial Quantikine Human sTNFRI and
sTNFRII kit (R&D Systems, USA) and the ELX 800 equipment
(Bio-Tek Instruments, USA).
Statistical analysis
The data are presented as the mean7SEM. The Pearson w2
analysis was used to test the differences between the groups
of patients depending on the gender. To evaluate statistical
significance, the U Mann–Whitney test was used for the
comparison of unpaired group data. The Wilcoxon matched
pairs test was applied to compare two variables. In
correlation observations, the Spearman correlation test
was used. A level of Po0.05 was assigned as significant.
Results
Lo¨fgren syndrome was diagnosed in 34.7% of patients; 48% of
female subjects and only 20.8% of male patients had acute
sarcoidosis. Lo¨fgren syndrome was significantly more fre-
quent in female patients than in male subjects (w2 ¼ 3.99,
Po0.05). Lo¨fgren syndrome patients were also significantly
younger compared to subjects without acute symptoms of
sarcoidosis (Po0.05). The distribution of gender between
patients with stage I, II, or III of sarcoidosis showed no
significant differences (w2 ¼ 1.65, P ¼ 0.199) (Table 1).
Patients’ gender and age had no influence on the
immunological parameters analyzed in BALF and PB.
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Table 2 BALF immunological analysis in patients with different manifestation of sarcoidosis.
Sarcoidosis
patients
Lo¨fgren
syndrome
patients
Patients
without
Lo¨fgren
syndrome
Patients in
sarcoidosis
stage I
Patients in
sarcoidosis
stage II or III
Lymphocytes (%) 42.56720.18 43.93720.78 41.03719.33 39.19720.14 45.18719.14*
Macrophages (%) 52.82720.72 53.08722.24 53.69719.71 56.95720.78 49.32719.49*
T lymphocytes (%) 90.6374.91 92.4073.33 89.9275.28* 90.8174.47 90.5375.43
B lymphocytes (%) 1.2071.11 0.8270.50 1.3371.19 1.1870.80 1.1871.30
NK cells (%) 4.0773.28 2.7271.17 4.6573.68** 3.4472.49 4.7173.89
Th lymphocytes (%) 74.02711.24 80.1777.28 71.48711.68** 75.60711.67 72.45710.88
Tc-s lymphocytes (%) 15.5579.83 10.7174.99 17.49710.72* 13.7879.87 17.2279.83
CD4:CD8 ratio 7.2375.23 9.7776.06 6.5275.51** 9.1277.00 5.8673.79
Activated T cells HLA
DR+ (%)
54.33714.36 57.087217.29 52.45714.48 49.88714.60 58.55713.46**
*Po0.05, **Po0.01.
Table 3 BALF immunological analysis in sarcoidosis patients with different disease course.
Remission group Stable disease group Progression
group
Lymphocytes (%) 40.0720.5 43.59716. 5 48.6717. 7**
Macrophages (%) 56.3721.7 50.6717.3 47719**
T lymphocytes (%) 9173.4 91.373.5 91.975.9
B lymphocytes (%) 0.9570.64 1.170.7 0.971.0
NK cells (%) 3.171.7 3.671.8 4.374.4
Th lymphocytes (%) 75.76710.60 78.677.7 7579.0
Tc-s lymphocytes (%) 14.4479.2 11.176.3 17.179.7
CD4:CD8 ratio 7.4374.57 9.7775.45 5.7673.0*
Activated T cells HLA DR+ (%) 54.2715.2 56.4717.2 61.0711.5*
*Po0.05, **Po0.01 remission vs. progression.
R. Kieszko et al.648In Lo¨fgren syndrome patients, the percentage of T lympho-
cytes and Th CD4+ lymphocytes in BALF was signifi-
cantly higher (Po0.05 and Po0.005, respectively)
compared to patients without acute symptoms of the
disease. In this group of patients, the CD4:CD8 ratio
had the highest value (Po0.01). The percentage of
BALF cytotoxic-suppressor CD8+ T lymphocytes and NK
cells was significantly lower (Po0.05 and Po0.005, respec-
tively) in Lo¨fgren syndrome patients than in other
subjects. In patients with hilar lymphadenopathy, the value
of BALF CD4:CD8 ratio was only slightly higher (P ¼ 0.056),
and the percentage of activated T lymphocytes HLA DR-
positive was significantly lower (Po0.01) compared to
patients with interstitial infiltrates (Table 2). Progression
group patients had a significantly lower value (Po0.05) of
BALF CD4:CD8 ratio and a significantly higher percentage
of activated HLA DR-positive T lymphocytes (Po0.05)
compared to remission group subjects (Table 3). Basic
immunological parameters in PB had similar values in all
examined groups.Assessment of sTNFRI and sTNFRII in PB serum and
BALF CCS
The level of sTNFRI in PB serum was similar in sarcoidosis
patients (629.957314.94 pg/ml) and in healthy subjects
(655.147164.28 pg/ml). But the concentration of serum
sTNFRII was significantly higher in sarcoidosis patients
(3454.1271391.88 pg/ml) compared to healthy subjects
(1601.217360.23 pg/ml; Po0.0001). The level of
soluble TNFRs in PB serum and BALF CCS was similar in all
examined groups of sarcoidosis patients. However, we
observed that patients without acute disease symptoms
and patients with parenchymal infiltrates in the lung showed
a tendency to higher levels of sTNFRs in PB serum and
lower levels of sTNFRs in BALF CCS compared to
subjects with Lo¨fgren syndrome and hilar lymphadenopathy
(Table 4, Fig. 1).
The level of sTNFRs in PB serum and BALF CCS was
also similar in patients with different clinical course of
sarcoidosis (Table 5). But we noticed a tendency to higher
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Table 4 sTNFRs level in different specimens of sarcoidosis patients.
Sarcoidosis
patients
Lo¨fgren syndrome
patients
Patients without
Lo¨fgren syndrome
Patients in
sarcoidosis stage I
Patients in
sarcoidosis stage
II or III
sTNFRI level in PB
serum (pg/ml)
629.957314.94 573.387332.63 660.017306.24 608.047348.26 650.997284.95
sTNFRI level in
BALF CCS (pg/ml)
27.11729.49 28.43726.01 26.42731.64 29.38723.01 24.31736.52
sTNFRII level in
PB serum (pg/ml)
3454.1271391.88 3373.3871263.86 3497.0171473.04 3325.0171374.26 3578.0671425.52
sTNRII level in
BALF CCS (pg/ml)
178.517183.45 199.947217.29 167.367167.02 208.887207.68 140.987145.60
±Std dev
±Std err.
Mean
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Figure 1 Serum sTNFRII level in patients with different radiological stages of sarcoidosis and in healthy subjects.
Table 5 sTNFRs level in sarcoidosis patients with different disease course.
Remission group Stable disease group Progression group
sTNFRI level in PB serum (pg/ml) 537.547312 660.287331 683.167283
sTNFRI level in BALF CCS (pg/ml) 27.28724 39.33749 18.74721.8
sTNFRII level in PB serum (pg/ml) 3274.071190 3621.471645 3849.2571681
sTNRII level in BALF CCS (pg/ml) 223.17233 163.87134 89.13766
TNF receptors and sarcoidosis 649levels of sTNFRs in BALF CCS and lower levels of sTNFRs in PB
serum of regression patients compared to patients with
further disease progression (Table 4, Fig. 2).
In serum specimens of sarcoidosis patients, there was a
nonsignificant positive correlation between sTNFRI and
sTNFRII level (R ¼ 0.19, P ¼ 0.145). BALF CCS sTNFRI
correlated significantly positively with sTNFRII levels in the
same specimen (R ¼ 0.52, P40.005).In all sarcoidosis patients, serum sTNFRII concentration
correlated positively with the percentage of BALF lympho-
cytes (R ¼ 0.28, P ¼ 0.055), the percentage of CD4+ cells
(R ¼ 0.31, Po0.05), and the CD4:CD8 ratio (R ¼ 0.36,
Po0.05). A significant negative correlation between TNFRII
level in blood serum and the percentage of BALF macro-
phages (R ¼ 0.29, Po0.05) as well as BALF CD8-positive
lymphocytes (R ¼ 0.36, Po0.01) was also found. TNFRI
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Figure 2 Serum sTNFRII in sarcoidosis patients with different course of the disease and in healthy subjects.
Figure 3 Flow cytometric analysis of CD120b expression on BALF CD4+ cells. (A) Lo¨fgren syndrome patients with low CD120b
expression on CD4+ cells. (B) Patients without acute symptoms of sarcoidosis with high CD120b expression on CD4+ cells.
R. Kieszko et al.650and TNFRII levels in BALF CCS correlated significantly
negatively with the percentage of activated T lymphocytes
with HLA DR antigen (R ¼ 0.5, Po0.001).TNFRI (CD120a) and TNFRII (CD120b) expression on
BALF and PB T lymphocytes
In sarcoidosis patients and healthy subjects, more than 80%
of BALF and PB T lymphocytes expressed both CD120a and
CD120b.The percentage of BALF double-positive CD8+/CD120a+
cells and CD8+/CD120b+ cells was the lowest in Lo¨fgren
syndrome patients and in patients with lymphadenopathy.
Patients with radiological stage I of sarcoidosis were
characterized by a high percentage of double-positive
CD4+/CD120a+ (Po0.05). In Lo¨fgren syndrome patients,
the expression of CD120a and CD120b on BALF CD4+ cells
was slightly lower compared to patients without acute
symptoms of the disease (Fig. 3). We found no significant
differences between patients with remission, stable disease,
and sarcoidosis progression as far as the percentage of
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Figure 4 PB CD4+/CD120b+ cell percentage in sarcoidosis patients with different disease course and in healthy subjects.
TNF receptors and sarcoidosis 651double-positive BALF cells and expression of examined
antigens was concerned.
The percentage of PB double-positive CD4+/CD120b+ cells
was significantly higher (Po0.005) in sarcoidosis patients
(32.4178.86%) than in healthy subjects (24.6672.72%).
Most interestingly, the percentage of double-positive CD4+/
CD120a+ and CD4+/CD120b+ cells in PB was significantly
higher (Po0.005) in patients with radiological stage I
sarcoidosis (34.1977.51% and 34.9577.07%, respectively)
than in subjects with RTG stage II or III (27.7478.56% and
29.5779.89%, respectively). The percentage of PB double-
positive CD4+/CD120b+ cells was significantly higher in
patients with stable disease (32.8577.6%, Po0.05) and
disease remission (35.4479.0%, Po0.001) compared to
healthy subjects. No significant differences were observed
between patients with sarcoidosis progression (26.6675.7%)
and healthy subjects (Figs. 4 and 5). We also found that
patients with spontaneous remission had a significantly
higher percentage of double-positive CD4+/CD120a+
(34.3579.17%) and double-positive CD4+/CD120b+
(35.4479.0%) cells than patients with sarcoidosis progres-
sion (25.775.4% and 26.6675.7%, respectively).
In PB, CD120b antigen expression on CD4+ and CD8+ cells
was significantly higher in sarcoidosis patients (Po0.001 and
Po0.01) than in healthy subjects. No significant differences
between sarcoidosis patients with different clinical outcome
were observed when comparing the expression of CD120a
and CD120b on PB CD4+ and CD8+ cells.
The percentage of BALF double-positive CD4+/CD120a+,
CD4+/CD120b, and CD8+/CD102b cells correlated signifi-
cantly positively with the percentage of PB cells (R ¼ 0.3,
Po0.05). Also, a positive correlation between the expres-
sion of CD120a and CD120b antigens on BALF and PB cells
was found (R ¼ 0.6, Po0.0001).The level of sTNFRI and sTNFRII in serum correlated
negatively with the percentage of BALF double-positive
CD4+/CD120a+ and CD4+/CD120b+ cells (Po0.05). However,
sTNFRI and sTNFRII levels in BALF CCS correlated positively
with the expression of CD120a and CD120b on BALF and PB T
cells (Po0.005).Discussion
Our results demonstrated that serum sTNFRs level estima-
tion may be highly useful in the prognosis of sarcoidosis
course. Therefore, our results are partly in accordance with
the findings of Nakayama et al. as well as Ziegenhagen et al.
Nakayama et al.14 measured plasma sTNFRI and and
sTNFRII levels in 19 patients with active sarcoidosis. The
levels of two receptor types were significantly increased in
sarcoidosis group. There was also a significant correlation
between the receptors’ level and the percentage of BALF
lymphocytes, but not the CD4/CD8 ratio. Nakayama et al.
found no differences in receptor plasma levels between
patients at different radiological stages and different
clinical outcome.
Ziegenhagen et al.13 determined sTNFRI and sTNFRII
serum levels in 49 patients with sarcoidosis. Serum levels
of two receptors were significantly higher in sarcoidosis
group compared to control group, but only sTNFRII was
significantly increased in sera of patients with radiological
stages II and III. The highest sTNFRII levels were observed in
patients with disease progression, whereas the lowest in
patients with spontaneous remission, and the differences
were close to significance. sTNFRI and sTNFRII correlated
positively with the percentage of BALF neutrophils and
eosinophils, but not with the percentage of lymphocytes or
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Figure 5 Flow cytometric analysis of CD120b expression on PB CD4+ cells. (A) Low percentage of double positive CD4+/CD120b+
cells characteristic of patients with RTG stage I of sarcoidosis with further disease remission. (B) High percentage of double positive
CD4+/CD120b+ cells in patients with RTG stage III of sarcoidosis with further disease progression. (C) Comparison of CD120b
expression on CD4+ cells of patients A and B.
R. Kieszko et al.652macrophages. Ziegenhagen and co-workers have suggested
that the level of two sTNFRs types is elevated in serum
specimens of sarcoidosis patients with active disease, but
only sTNFRII seems to be useful in the monitoring of disease
inflammatory activity. Inclusion criteria for the examined
group of patients may explain the differences between
Ziegenhagen’s and our results. Ziegenhagen et al. excluded
Lo¨fgren syndrome patients (‘‘classic acute presentation’’),
assuming good clinical prognosis in that group of patients.
On the other hand, the investigators included a large group
of patients with severe and chronic disease. On the contrary,
our examined group consisted of newly diagnosed patients,
with a high percentage of Lo¨fgren syndrome cases.
Also, our results demonstrated a higher concentration of
sTNFRII, but not sTNFRI, in serum samples of sarcoidosis
patients compared to the control group. We also found a
tendency to higher sTNFRs levels in patients with radi-
ological stage II or III, and patients with further progressionof sarcoidosis compared to patients with radiological stage I,
and patients without disease progression. sTNFRs level
correlated with other immunological prognostic factors such
as the percentage of BALF lymphocyte, and activated HLA
DR+ T cells.
Dai et al.15 measured the production of sTNFRs in alveolar
macrophages (AM) culture supernatants from 10 patients
with sarcoidosis and nine control subjects. Compared to the
control group, spontaneous and lipopolysaccharide (LPS)-
stimulated production of sTNFRs and TNF-a was significantly
increased in sarcoidosis patients. The concentration of two
sTNFRs types, but mainly of sTNFRII, was closely related to
that of TNF-a. LPS-induced increase was 1.5-fold for sTNFRI,
at least four-fold for sTNFRII, and at least 25-fold for TNF-a
in all examined patients. These results indicate that AMs can
release two sTNFRs in relation with TNF-a. sTNFRII may be
more liable to shedding than sTNFRI. The authors concluded
that both sTNFRI and sTNFRII may be involved in the
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TNF receptors and sarcoidosis 653pathogenesis of sarcoidosis, possibly as counter-regulators
of TNF-a.15
Similar results were obtained by Hino and co-workers.16
They evaluated BALF sTNFRs level in 13 sarcoidosis patients
and 18 control subjects using ELISA. Type II, but not type I
sTNFR in BALF was significantly elevated in sarcoidosis
patients compared to healthy nonsmokers. Although the
levels of sTNFRI in BALF of sarcoidosis patients were not
correlated with any cellular profile of BALF, the concentra-
tions of type II receptor correlated significantly with the
number of BALF lymphocytes. In their study, Hino et al.
included, however, six sarcoidosis patients who received
corticosteroid therapy.16
We were not able to assess sTNFRI and sTNFRII on BALF
CCS in the control group, but we found a tendency to higher
levels of sTNFRs in BALF CCS in the group of Lo¨fgren
syndrome patients, radiological stage I, and spontaneous
remission compared with the group of patients without
acute symptoms, radiological stage II/III, and patients with
disease progression. Moreover, we showed a significant
correlation between sTNFRs levels in PB and BALF as well
as the dependence between sTNFRs concentration and TNFR
expression on T cells in different specimens. It may
contribute to the progression of systemic immunologic
response in sarcoidosis, and may show that the cytokine
network could play an important role in sarcoidosis devel-
opment and prolongation.
Armstrong and co-workers11 have attempted to explain
that phenomenon. The investigators found a reduced TNF-a
bioactivity in AM supernatants derived from sarcoidosis
patients with stage I compared to those with stage II/III and
the control group. That contrasted with increased sTNFRI
levels in AM culture supernatants derived from subjects with
stage I compared to patients with stage II/III and healthy
subjects. The authors concluded that the inhibition of TNF-a
bioactivity by increased sTNFRs levels may be higher in
patients with radiological stage I than in those with stage II
or III, and this may represent a homeostatic protective
mechanism against an excessive TNF production character-
istic for chronic inflammation.11
The hypothesis concerning the role of sTNFRs in patho-
logical process limitation may become useful in the
development of new therapeutic strategies of sarcoidosis
management. Corticosteroids are usually effective in block-
ing TNF-a cell release. Other agents that nonspecifically
inhibit TNF-a release include methotrexate, azathiopryne,
and pentoxiphylline. Specific TNF-antagonizing biological
agents such as infiximab, etanercept, and adalimumab are
tested in sarcoidosis patients, with various results.17–20 Utz
et al.17 showed that in patients with progressive stage II or III
of pulmonary sarcoidosis, etanercept was frequently asso-
ciated with an early or late treatment failure. The authors
concluded that neither absolute levels of TNF-a nor TNF-a
activity in blood serum, BALF, or supernatant of alveolar
macrophages culture were able to predict which patients
would respond to etanercept.
Little is known about the expression of two TNFRs
presented on BALF and PB cell surface in sarcoidosis. Dai
et al.21 found the expression of Fas receptor (FasR) and
TNFRI on the higher percentage of AM in sarcoidosis in
comparison with control subjects. FasR and TNFRI are
recognized as apoptotic signaling receptors. The authorssuggested that alveolar macrophages of sarcoidosis patients
undergo more apparent apoptosis than those of control
subjects.21
Using a flow cytometry technique, Gaede et al.22 showed
that CD120a is predominantly expressed on alveolar macro-
phages, and CD120b was mainly expressed on lymphocytes,
macrophages, and PB mononuclear cells in the group of
patients with different pulmonary disorders. The authors
found 0.8% CD120a-positive blood lymphocytes and 36.23%
CD120b-positive blood lymphocytes in the group of four
patients. BALF cells were collected from 14 patients; 4.13%
and 25.48% of BALF lymphocytes were CD120a- and CD120b-
positive.22 Agostini and co-workers12 could not detect the
CD120a antigen on T lymphocytes and the CD120b antigen
on CD4-positive T cells of sarcoidosis patients. Recently,
Chen and co-workers23 found a higher expression of TNFRII
on lymphocytes from patients with hypersensitivity pneu-
monitis than in the control group, and patients with
interstitial pulmonary fibrosis.
In our group of patients, more than 80% of BALF and PB
lymphocytes expressed both CD120a and CD120b antigens.
An increased expression provides more sites for TNF-a
binding, and may enhance immunological reaction in
sarcoidosis contributing to alveolitis and granuloma forma-
tion. Differences in TNFRs expression may be due to the
influence of different levels of various cytokines: IFN-g,24
IL-2,25 IL-1, and TNF-a.26 Therefore, in order to explain the
relationship, precise investigations of a whole cytokine
network is required.
The measurement of PB double-positive CD4+/CD120b+
cell percentage is interesting. High percentage of these cells
seems to be characteristic of sarcoidosis patients with
further disease remission. These findings could indicate the
role of these cells in downregulation of a cell-mediated
immunological response. Immunophenotyping of PB cells
may also serve as a convenient prognostic marker of
sarcoidosis.Acknowledgment
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